Evaluation of NPP1 as a Novel Biomarker of Coronary Artery Disease: A Pilot Study in Human Beings

Amir Hooshang Mohammadpour1,2, Saeed Nazemi1, Fatemeh Mashhadi2, Atefeh Rezapour2, Mohammad Afshar3, Sepideh Afzalnia3, Afsaneh Mohammadi1, Hamid Reza Mashreghi Moghadam4, Maryam Moradian5, Seyed Mohammad Hasan Moallem6, Saeed Falahaty2, Azadeh Zayerzadeh2, Sepideh Elyasi7,8

1Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
2Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
3Research and Education Department, Razavi Hospital, Mashhad, Iran.
4Department of Anatomy, Birjand University of Medical Sciences, Birjand, Iran.
5Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
6Birjand Cardiovascular Disease Research Center; Department of Cardiology, Birjand University of Medical Sciences, Birjand, Iran.
7Department of Pediatric Cardiology, Rajaie Cardiovascular Medical and Research Center, Tehran, Iran.
8School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Keywords:
- Coronary Artery Calcification
- ENPP1
- Biomarker
- Inorganic pyrophosphate
- Glycoprotein 1- nucleotides

Abstract

Purpose: Coronary artery calcification (CAC) is utilized as an important tool for global risk assessment of cardiovascular events in individuals with intermediate risk. Ecto phosphodiesterase/nucleotide phosphohydrolase-1 (ENPP1) converts extracellular nucleotides into inorganic pyrophosphate and it is a key regulator of tissue calcification that adjusts calcification in tissues like vascular smooth muscle cells. The main purpose of this clinical study was to find out the correlation between ENPP1 serum concentration and CAC in human for the first time.

Methods: In this study 83 patients (16 diabetic patients and 67 non-diabetic patients) with coronary artery disease who fulfilled inclusion and exclusion criteria, entered the study. For all patients a questionnaire consisting demographic data and traditional cardiovascular risk factors were completed. Computed tomography (CT)-Angiography was carried out to determine coronary artery calcium score and enzyme-linked immunosorbent assay (ELISA) method was used for measuring ENPP1 serum concentrations.

Results: There was a reverse significant correlation between ENPP1 serum concentration and total CAC score and also CAC of right coronary artery (RCA) (P<0.05) in non-diabetic patients.

Conclusion: On the basis of our results, ENPP1 serum concentration may be a suitable biomarker for coronary artery disease at least in non-diabetic patients. However, more studies with higher sample size are necessary for its confirmation.

Introduction

Vascular calcification is a life threatening complication of cardiovascular disease and an independent risk factor for high morbidity and mortality.1 It is an inevitable process particularly in the advanced stages of atherosclerosis which can cause the plaque rupture. Coronary artery calcification (CAC) is a surrogate marker for subclinical atherosclerosis and recently determined as strong predictor that comforts the prediction of future cardiovascular events particularly in intermediate risk subjects. It is determined by electron beam-computed tomography (EBCT).2 Increased coronary artery calcium score (CACS) correlates with the risk of cardiovascular disease.3 Recent studies have provided impetus to shift from cellular interaction based calcification models to models emphasizing on the important role of extracellular matrix in calcification. Adenosine triphosphate (ATP) and other nucleotides and nucleosides play different biochemical roles depending on differential tissue expression, cell distribution, and substrate availability and their presence in either the intracellular or extracellular compartment. Ecto-nucleotidases classified to four families including ecto-nucleotide pyrophosphatase / phosphodiesterase (ENPP) family. ENPP1 is a member of ENPP family that expresses in different tissues including cartilage, kidney, heart, parathyroid and skeletal muscle, and to a greater extent in vascular smooth muscle cells (VSMCs), osteoblasts and chondrocytes.4,5 NPP1 is known to play vital roles in calcium/phosphate regulation, and repression of soft tissue mineralization, and maintaining skeletal

*Corresponding author: Sepideh Elyasi, Tel: +98 51 31801588, Fax: +98 51 38823251, Email: Elyasis@mums.ac.ir
©2018 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
structure and function. NPP1 hydrolyses ATP to produce either inorganic pyrophosphate (PPi) plus adenosine monophosphate (AMP) or inorganic phosphate (Pi) plus adenosine diphosphate (ADP) in a two stage process via either ADP or a phosphate bound intermediate.\(^7\) PPi is a central regulator of calcification in the extracellular matrix. In extracellular, PPi, draw ups gene expression and cellular differentiation, which have main physiologic effects on chondrogenesis and expression of osteopontin. PPi, strongly inhibits the nucleation and advancement of hydroxyapatite (HA) and other basic calcium phosphate crystals.\(^7,10,11\) Therefore, through generating PPI, NPP1 is a key regulator of tissue calcification and bone development and can be effective in prevention of pathologic tissue calcification.

According to this, we evaluated the ENPP1 as a diagnostic biomarker in human to determine the extent of coronary artery calcification.

**Materials and Methods**

**Patients**

Eighty-three patients, who aged higher than 40 years old with diagnosis of coronary artery disease by angiography which was performed by the cardiologist, were enrolled in this study between November 2015 and March 2016. This test is the best way to detect coronary artery disease (CAD) in the arteries, over 51% of which are blocked by atherosclerotic plaques and useful in detecting the vessels responsible for advanced CAD. However, it does not provide information about the artery wall and atherosclerosis may not be diagnosed that has not yet captured the duct.\(^12\) Patients with >50% coronary stenosis of at least one artery were considered as CAD+ and included in study. Patients were recruited from Cardiology ward of Razavi Hospital, Mashhad, Iran. This study was accepted by ethics committee of Mashhad University of Medical Sciences (code: 931459). All patients signed the consent form prior to entry in the study. All patients signed the consent form prior to entry in the study.

Patients with calcium and phosphor metabolic disorder or receiving medications which are effective on calcium and/or phosphate and immunosuppressant or antioxidant medications, intake of folic acid and methotrexate, malignancies, heart failure, hyp or hyper parathyroidism, renal insufficiency, history of osteoarticular disorders and chronic inflammatory diseases, and acute infection during the study were excluded from the study. A questionnaire containing demographic data, laboratory data, drug and medical and familial history of cardiovascular risk factors was completed for all patients.

**Determination of ENPP1 serum concentration and CAC**

Twenty milliliter of whole blood was collected from patients and centrifuged at 2500 rpm for 10 min. Two milliliter serum were isolated and divided into 4 micro sets of 0.5 ml. The serum was stored at -70 °C until required for analysis. Routine biochemical measurements such as plasma glucose, total cholesterol (TC), triglycerides, low density lipoprotein Cholesterol (LDL-c), high-density lipoprotein cholesterol (HDLC-c), and serum calcium and phosphorus level were carried out by routine laboratory methods. Serum level of soluble ENPP1 was measured with an enzyme-linked Immunosorbant assay (ELISA) -kit (Zellbio, Germany); each assay was calibrated using ENPP1 standard curve following the manufacturer’s instructions. Coronary Artery Calcification score of left main coronary artery (LMCA), left anterior descending (LAD) and circumflex (CX) and right coronary artery (RCA) was determined by high resolution B mode ultrasonography in radiology department of Razavi Hospital. CAC measurement is now considered a potentially useful test for improving coronary risk assessment in selected intermediate-risk asymptomatic patients in whom high CAC scores signify increased cardiovascular risk beyond that predicted by conventional cardiovascular risk factors alone. Agatston score is a semi-automated tool to calculate a score based on the extent of coronary artery calcification detected by an unenhanced low-dose CT scan which is routinely performed in patients undergoing cardiac CT. Due to an extensive body of search, it allows for an early risk stratification as patients with a high Agatston score (>160) have an increased risk for a major adverse cardiac event. Although it does not allow for the assessment of soft non-calcified plaques, it has shown a good correlation with contrast enhanced CT coronary angiography.\(^13,14\)

However, it should be defined that when the pretest probability of coronary artery disease is low (eg, asymptomatic screening setting), a CAC score of zero is associated with low risk of coronary artery disease and low risk of near-term coronary events but in older asymptomatic patients with risk factors, CAC=0 is associated with a moderate increased risk of events and in patients with clinical signs and symptoms associated with an intermediate-to-high risk of coronary disease, CAC=0 is often associated with myocardial ischemia on provocative testing and with a high risk of near-term coronary events.\(^15\)

**Statistical Analysis**

Data recruited from the standard forms were gathered and then analyzed with SPSS version 16.0 (Systat Software, Inc., Chicago, IL). For descriptive assessment, mean ± standard deviations of continuous variables were provided. For nominal variables, number and percentages were reported. Correlation between Serum Concentration of ENPP1 with CAC was analyzed using spearman correlation test. Chi-squared test and t test were applied for continuous and nominal data, where appropriate. Results were considered significant at p<0.05.

**Results**

**Characteristics of the study Population**

The study population consists of 83 patients, male (77%) and female (23%). The mean age of population was
Table 1. patients characteristic, laboratory data, traditional cardiovascular risk factors and mean ENPP1 serum level of patients

| Patients characteristic | All patients (n=83) (Mean±SD) | Diabetic patients (n=16) (Mean±SD) | Non-diabetic patients (n=67) (Mean±SD) | P value |
|-------------------------|-------------------------------|-----------------------------------|-----------------------------------|---------|
| Age (year)              | 57.13±10.7                    | 56.4±10.52                        | 57.74±10.65                      | 0.95*   |
| BMI (kg/m²)             | 28.36±4.78                    | 28.46±3.8                        | 27.99±5.46                      | 0.43*   |
| Female/male ratio       | 0.29                          | 0.54                              | 0.32                             | 0.005** |
| Laboratory tests        | Mean±SD                       |                                   |                                   |         |
| HDL-C (mg/dl)           | 41.92±9.97                    | 40.76±9.14                       | 45.24±15.68                     | 0.66*   |
| LDL-C (mg/dl)           | 90.81±29.14                   | 95.88±34.56                      | 88.69±28.04                      | 0.06*   |
| Total cholesterol (mg/dl)| 163.30±33.32                 | 165.76±38.28                     | 164±33.81                       | 0.09*   |
| FBS (mg/dl)             | 104.56±24.00                  | 141.2±44.05                      | 97.57±14.71                     | 0.005*  |
| Traditional risk factors| Frequency (%)                 |                                   |                                   |         |
| Hypertension (%)        | 45.88                         | 60                                | 45.34                           | 0.005** |
| Dyslipidemia (%)        | 63.52                         | 65                                | 61.62                           | 0.63*   |
| Positive family history (%) | 51.76                      | 47.62                            | 62.79                           | 0.005** |
| Diabetes (%)            | 20.58                         | 100                              | 0                               | -       |
| Current Smoking (%)     | 35.29                         | 33.33                            | 23.25                           | 0.66*   |
| Concentration of ENPP1  | 106.42±78.54876               | 132.62±100.5                     | 100.26±71.97                    | 0.14    |

BMI: Body Mass Index, HDL-C: High Density Lipoprotein-Cholesterol, LDL-C: Low Density Lipoprotein-Cholesterol, FBS: Fast Blood Sugar, ENPP1: Ectonucleotide pyrophosphatase/phosphodiesterase

* P value<0.05 is considered significant

Correlation between ENPP1 serum level and Coronary Artery Calcification agatson score

There was a reversed significant correlation between ENPP1 serum level and total coronary artery calcification score and CAC score of RCA in non-diabetic patients (P<0.05) but, there was no significant correlation between ENPP1 serum level and CAC score ofLMCA, LAD and CX (P>0.05) (Table 2)

Table 2. Correlation between ENPP1 serum concentration with LAD, RCA, LMCA, and CX coronary artery calcification score

| Coronary artery Calcium score | Mean ±SD | P value Spearman Correlation Test | Correlation coefficient |
|-------------------------------|----------|----------------------------------|-------------------------|
| Total calcification of coronary vessels (agatson score) | 357.29±590.81 | 0.004                            | -0.121                  |
| Calcification in coronary LAD (agatson score) | 184.60±304.46 | 0.345                            | 0.044                   |
| Calcification in coronary RCA (agatson score) | 63.37±101.86 | 0.00                              | -0.22                   |
| Calcification in coronary CX (agatson score) | 44.86±99.00 | 0.416                            | -0.264                  |
| Calcification in coronary LMCA (agatson score) | 34.11±116.00 | 0.494                            | -0.107                  |

CAC: Coronary Artery Calcification, LAD: Left Anterior Descending, RCA: Right Coronary Artery, LMCA: Left Main Coronary Artery, CX: Circumflex

Moreover, based on Rumberger method we divided patients based on their total CAC to three groups; mild (CAC lower than 25th of range), moderate (between 25th and 75th of range) and severe (≥75th of CAC range). Fifty-four percent of the patients were in mild group and 44.4% and 1.6% were in moderate and severe groups, respectively. There was no significant difference between ENPP1 serum level of these groups (P>0.05).

Discussion

In this study, the correlation of the ENPP1 serum level with CAC was evaluated for the first time in human. As mentioned in results, there was a significant reversed correlation between ENPP1 serum level and total and RCA CAC score in non-diabetic patients (P<0.05) but no significant correlation with CAC score of LAD, LM and CX (P ≥0.05). Several In vitro and In vivo studies have been conducted on the relationship between coronary artery calcification and serum ENPP1 level previously but they were only limited to the examination of genetic disorders and gene mutations of ENPP1 in infants and evaluation of the relationship between serum levels of ENPP1 and calcification of atherosclerotic plaques in diabetic patients.

Based on previous studies, it is entirely apparent that the calcification is suppress by ENPP1 by means of PPi, that it is a potent inhibitor of hydroxyl apatite (HA) crystal formation in mineralized competent of tissues.
NPPs can convert AMP into adenosine and P_i, although conflicting reports suggest that AMP competitively inhibits NPP activity. P Pi is hydrolyzed by tissue-nonspecific alkaline phosphatase (TNAP) into inorganic phosphate (Pi), which co-crystallizes with calcium into HA and thereby promotes bone formation. Thus, P Pi has a dual role as it can both suppress and promote HA crystal deposition, depending on the expression ratio and catalytic activities of NPP1 and TNAP. The distorted balance of Pi/P Pi ultimately leads to pathological calcification.16-19 In another study, NPP1-deficient mice showed reduced levels of extracellular P Pi, causing pathological calcification of cartilage and soft tissues, such as arterial smooth muscle walls and also abnormal bone development.16,17 So, according to the previous studies, it is clear that NPP1 and PP Pi, physiologically work to prevent calcification of arteries and certain other soft tissues.20,21 This study was the first clinical study that evaluated the relationship between serum concentrations of ENPP1 and coronary artery calcification in patients with chronic heart ischemia. According to the results mentioned above, there was a significant reversed relationship between the coronary artery calcification and this biomarker in non-diabetic patients.

A study was conducted in 2010 by Jeong et al. which assessed the relationship between coronary artery calcification and ENPP1 gene expression levels in 140 diabetic patients. None of patients had history of cardiovascular disease and no relationship was found between coronary artery calcification and ENPP1 gene expression levels.22 In present study 16 diabetic patients and 67 non-diabetic patients were included and no relationship was found between total coronary artery calcification score and serum concentrations of ENPP1. However, after exclusion of diabetic patients a significant relationship was observed (P = 0.004). Nowadays type 2 diabetes prevalence is increasing steadily all over the world. One of the criteria for type 2 diabetes, is insulin resistance in different body tissues such as skeletal muscle, liver and fat tissues that occurs due to impaired peripheral receptor signaling of insulin. In several studies it has been observed that ENPP1, which is connected directly to the insulin receptor α, impairs receptor function and then reduces the signaling cascade, in a wide variety of tissues such as skeletal muscle and liver.23 In some other studies has been observed that the expression level of ENPP1 in patients with insulin resistance has been increased and also it is mentioned that regulatory increased ENPP1 level in rat liver, induces insulin resistance and glucose tolerance.24-26 In a multicenter clinical study conducted in Italy and America in 2005, it is observed that increased expression of ENPP1 is associated with a higher prevalence of diabetes and myocardial infarction.27 So, in this research, we excluded patients with type 2 diabetes and it was found that the level of serum ENPP1 is affected by type 2 diabetes and there is a significant negative relationship between the ENPP1 serum levels and the total calcification score of coronary arteries in non-diabetic patients with cardiovascular disease.

This significant negative correlation was also found by CAC of RCA but not the other coronary arteries. It may be due to non-uniform distribution of other vessels’ calcium scores resulting from small sample size. So, limited number of patients included in this study is the major limitation of this study.

Conclusion
In this study, the correlation of the ENPP1 serum level with CAC was clinically evaluated for the first time in patients with coronary artery disease. There was a reverse significant correlation between ENPP1 serum level and total CAC and CAC of RCA in non-diabetic patients (P<0.05), but there was no significant correlation between ENPP1 serum level patients and LAD, LM and CX (P >0.05). Further studies are recommended in this field with higher sample size.

Acknowledgments
This study is part of a research thesis for a Pharm.D. degree at Mashhad University of Medical Sciences. The authors are thankful for the funding of this study by the Research Council of Mashhad University of Medical Sciences.

Ethical Issues
The study protocol was approved by the ethical committee of Mashhad University of Medical Sciences.

Conflict of Interest
The authors have no conflicts of interest.

References
1. Santos RD, Nasir K, Carvalho JA, Raggi P, Blumenthal RS. Coronary calcification and coronary heart disease death rates in different countries, not only the influence of classical risk factors. Atherosclerosis 2009;202(1):32-3. doi: 10.1016/j.atherosclerosis.2008.04.017
2. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al. Assessment of coronary artery disease by cardiac computed tomography: A scientific statement from the american heart association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and committee on cardiac imaging, council on clinical cardiology. Circulation 2006;114(16):1761-91. doi: 10.1161/circulationaha.106.178458
3. Abedin M, Tintut Y, Demer LL. Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004;24(7):1161-70. doi: 10.1161/01.atv.0000133194.94939.42
4. Niitschke Y, Weissen-Penz G, Terkeltaub R, Rutsch F. Npp1 promotes atherosclerosis in apo e knockout mice. J Cell Mol Med 2011;15(11):2273-83. doi: 10.1111/j.1582-4934.2011.01327.x
5. Terkeltaub RA. Inorganic pyrophosphate generation and disposition in pathophysiology. *Am J Physiol Cell Physiol* 2001;281(1):C1-c11. doi: 10.1152/ajpcell.2001.281.1.C1

6. Johnson K, Terkeltaub R. Inorganic pyrophosphate (ppi) in pathologic calcification of articular cartilage. *Front Biosci* 2005;10:988-97.

7. Bollen M, Gijsbers R, Ceulemans H, Stalman W, Stefan C. Nucleotide pyrophosphatases/phosphodiesterases on the move. *Crit Rev Biochem Mol Biol* 2000;35(6):393-432. doi: 10.1080/10409230091169249

8. Stefan C, Jansen S, Bollen M. Modulation of purinergic signaling by npp-type ectophosphodiesterases. *Purinergic Signal* 2006;2(2):361-70. doi: 10.1007/s11302-005-5303-4

9. Goding JW, Terkeltaub R, Maurice M, Deterre P, Sali A, Belli SI. Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells: Structure and function of the pc-1 family. *Immunol Rev* 1998;161:11-26.

10. Terkeltaub R. Physiologic and pathologic functions of the NPP1 nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. *Purinergic Signal* 2006;2(2):371-7. doi: 10.1007/s11302-005-5304-3

11. Addison WN, Azari F, Sorensen ES, Kaartinen JS, McCue MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. *J Biol Chem* 2007;282(21):15872-83. doi: 10.1074/jbc.M701116200

12. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; 2012.

13. van der Bijl N, Joemai RM, Geleijns J, Bax JJ, Schuijf JD, de Roos A, et al. Assessment of agatston coronary artery calcium score using contrast electron beam cimography. *Circulation* 2000;102(14):e163-8. doi: 10.1161/01.CIR.102.14.163

14. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with calcium score of zero? The importance of conditional probability. *Circulation* 2000;102(14):e163-8. doi: 10.1161/01.CIR.102.14.163

15. Greeneland P, Bonow RO. How low is the calcium score of zero? The importance of conditional probability. *Circulation* 2008;117(13):1627-9. doi: 10.1161/circulationaha.107.767665

16. Hessel L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. *Proc Natl Acad Sci U S A* 2002;99(14):9445-9. doi: 10.1073/pnas.142063399

17. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis mediated by Ppi depletion promotes spontaneous aortic calcification in NPP1-/ mice. *Arterioscler Thromb Vasc Biol* 2005;25(4):686-91. doi: 10.1161/01.ATV.0000154774.71187.f0

18. Ciancaglini P, Yadav MC, Simao AM, Narisawa S, Pizauro JM, Farquharson C, et al. Kinetic analysis of substrate utilization by native and TNAP-, NPP1-, or PHOSPHO1-deficient matrix vesicles. *J Bone Miner Res* 2010;25(4):716-23. doi: 10.1359/jbmr.091023

19. Harney D, Hesse L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: An integrated model of the pathogenesis of mineralization disorders. *Am J Pathol* 2004;164(4):1199-209. doi: 10.1016/s0002-9440(10)63208-7

20. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S. Mutation in nppa in a mouse model of ossification of the posterior longitudinal ligament of the spine. *Nat Genet* 1998;19(3):271-3. doi: 10.1038/s5

21. Mackenzie NC, Zhu D, Milne EM, van ‘t Hof R, Martin A, Darryl Quarels L, et al. Altered bone development and an increase in FGF-23 expression in enpp1(-/-) mice. *PLoS One* 2012;7(2):e32177. doi: 10.1371/journal.pone.0032177

22. Jeong DJ, Lee DG, Kim HJ, Cho EH, Kim SW. ENPP1 K121Q genotype not associated with coronary artery calcification in Korean patients with type 2 diabetes mellitus. *Korean Diabetes J* 2010;34(5):320-6. doi: 10.4093/kdj.2010.34.5.320

23. Seo HJ, Kim SG, Kwon OJ. The K121Q polymorphism in ENPP1 (PC-1) is not associated with type 2 diabetes or obesity in Korean male workers. *J Korean Med Sci* 2008;23(3):459-64. doi: 10.3346/jkms.2008.23.3.459

24. Graru N, Urhammer SA, Ek J, Albrechtsen A, Glumer C, Borch-Johnsen K, et al. Studies of the relationship between the enpp1 k121q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 danish white subjects. *Diabetologia* 2006;49(9):2097-104. doi: 10.1007/s00125-006-0353-x

25. Meyre D, Bouatia-Naji N, Vatin V, Veslot J, Samson C, Tichet J, et al. Enpp1 K121Q polymorphism and obesity, hyperglycaemia and type 2 diabetes, insulin resistance and obesity in the ENPP1 K121Q polymorphism not associated with type 2 diabetes or obesity in 7,333 danish white subjects. *Diabetologia* 2006;49(9):2097-104. doi: 10.1007/s00125-006-0353-x

26. McAteer JB, Prudente S, Bacci S, Lyon HN, Hirschhorn JN, Trischitta V, et al. The ENPP1 K121Q polymorphism is associated with type 2 diabetes in european populations: Evidence from an updated meta-analysis in 42,042 subjects. *Diabetes* 2008;57(4):1199-209. doi: 10.1007/s00125-006-0353-x

27. Bacci S, Ludovico O, Prudente S, Zhang YY, Di Paola R, Mangiacotti D, et al. The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction. *Diabetes* 2005;54(10):3021-5.